Tenoxicam


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Rheumatoid arthritis; Osteoarthritis; Acute musculoskeletal disorders 20 mg as a single dose daily. IM/IV Rheumatoid arthritis; Osteoarthritis; Acute musculoskeletal disorders 20 mg as a single dose for 1-2 days, continued w/ the oral form. Treatment duration: Up to 7 days for acute musculoskeletal disorders and up to 14 days for severe cases.
Dosage Details
Oral
Acute musculoskeletal disorders, Osteoarthritis, Rheumatoid arthritis
Adult: 20 mg as a single dose, taken at the same time each day. Treatment duration: Up to 7 days for acute musculoskeletal disorders and up to 14 days for severe cases.
Elderly: Use the lowest effective dose for the shortest possible duration.

Parenteral
Acute musculoskeletal disorders, Osteoarthritis, Rheumatoid arthritis
Adult: Initially, 20 mg IM/IV as a single dose given for 1-2 days, to be continued w/ the oral form, administered at the same time each day. Treatment duration: Up to 7 days for acute musculoskeletal disorders and up to 14 days for severe cases.
Elderly: Use the lowest effective dose for the shortest duration.
Administration
Should be taken with food. Take w/ or immediately after meals.
Reconstitution
Dissolve lyophilisate in 2 mL of sterile water for inj.
Contraindications
Hypersensitivity to tenoxicam, aspirin or other NSAIDs. History of or active peptic ulceration, GI bleeding (melaena, haematemesis) or severe gastritis; severe heart failure. Last trimester of pregnancy.
Special Precautions
Patient w/ history of or active bronchial asthma, uncontrolled HTN, CHF, established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, risk factors for CV disease (e.g. HTN, hyperlipidaemia, DM, smoking), history of GI disease, fluid retention and oedema. Patient who will undergo major surgery (e.g. joint replacement). Elderly. Renal and hepatic impairment.
Adverse Reactions
Dyspepsia, nausea, abdominal pain and discomfort, constipation, diarrhoea, flatulence, indigestion, epigastric distress, stomatitits, anorexia; peripheral oedema; headache, dizziness; allergic reactions, asthma, bronchospasm, dyspnoea, rash, pruritus; decreased Hb, anaemia, thrombocytopenia, non-thrombocytopenic purpura, leucopenia, eosinophilia, epistaxis; increased serum transaminase levels; swollen eyes, blurred vision, eye irritation, malaise, tinnitus; oedema, HTN, cardiac failure.
Potentially Fatal: Peptic ulceration, GI bleeding, anaphylaxis, Lyell's syndrome, Stevens-Johnson syndrome, exfoliative dermatitis, nephrotoxicity, arterial thrombotic events (e.g. MI or stroke), hepatitis, jaundice.
MonitoringParameters
Monitor renal, hepatic and cardiac functions.
Overdosage
Symptoms: Headache, nausea, vomiting, epigastric pain, GI bleeding, rarely diarrhoea, disorientation, excitation, coma, drowsiness, dizziness, tinnitus, fainting, occasionally convulsions. Acute renal failure and liver damage may occur. Management: Symptomatic treatment. Ensure good urine output. Frequent or prolonged convulsions should be treated w/ IV diazepam. May administer an H2-antagonist.
Drug Interactions
Increased risk of adverse effects (particularly GI) w/ salicylates and other NSAIDs. May enhance the anticoagulant effect of warfarin and other anticoagulants. May reduce the effect of antihypertensive drugs. Increased risk of nephrotoxicity w/ ciclosporin. Increased risk of convulsions w/ quinolones. May decrease the elimination of lithium. May interfere w/ the natriuretic action of diuretics. May enhance the toxicity of methotrexate. May reduce the effects of mifepristone. Increased risk of GI bleeding w/ corticosteroids.
Food Interaction
Food may delay the rate of absorption.
Action
Description: Tenoxicam is an NSAID which has marked anti-inflammatory and analgesic activity and some antipyretic activity. As w/ other NSAIDs, the precise mode of action is unknown, though it is probably multifactorial, involving inhibition of prostaglandin biosynthesis and reduction of leucocyte accumulation at the inflammatory site.
Pharmacokinetics:
Absorption: Well absorbed from the GI tract. Rapidly absorbed after IM inj. Food may delay the rate (to approx 6 hr) of absorption. Time to peak plasma concentration: Approx 2 hr.
Distribution: Penetrates synovial fluid. Plasma protein binding: Approx 99%.
Metabolism: Completely metabolised to inactive metabolites.
Excretion: Mainly via urine, some via bile as glucoronide conjugates of the metabolites. Plasma elimination half-life: 42-81 hr.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store below 30°C.
Disclaimer: This information is independently developed by MIMS based on Tenoxicam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Analcam
  • Sinoral
  • Tilcotil
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in